Shapiro Capital Management LLC Sells 55,133 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Shapiro Capital Management LLC cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 945,127 shares of the medical equipment provider's stock after selling 55,133 shares during the period. Zimmer Biomet comprises about 3.4% of Shapiro Capital Management LLC's holdings, making the stock its 9th largest holding. Shapiro Capital Management LLC owned about 0.47% of Zimmer Biomet worth $99,834,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Dodge & Cox boosted its position in shares of Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after acquiring an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock worth $1,559,147,000 after acquiring an additional 176,337 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after acquiring an additional 218,688 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after purchasing an additional 2,796,372 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Zimmer Biomet by 7.6% in the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock valued at $250,367,000 after purchasing an additional 167,435 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

ZBH stock traded down $1.15 on Monday, reaching $95.80. 2,133,961 shares of the company's stock were exchanged, compared to its average volume of 1,756,116. The stock has a fifty day moving average of $103.41 and a 200-day moving average of $105.84. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.92 and a twelve month high of $120.13. The firm has a market cap of $18.95 billion, a PE ratio of 21.53, a P/E/G ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet's revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.94 earnings per share. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.00%. The ex-dividend date was Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Morgan Stanley reduced their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group reduced their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Wells Fargo & Company reduced their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Finally, JMP Securities reduced their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $113.45.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.